Study Identifies Key Factors Influencing Weight Loss on GLP-1 RA Medications

Cleveland Clinic research reveals that medication type, dosage, treatment purpose, and persistence significantly impact weight reduction outcomes.

Semaglutide, marketed as Wegovy and Ozempic, was found to be more effective for weight loss than liraglutide, sold as Saxenda and Victoza.
Patients treated for obesity experienced greater weight reduction compared to those treated for type 2 diabetes, with higher doses yielding better results.
Persistence with medication is crucial; those who continued treatment for a year saw significantly more weight loss than those with shorter coverage periods.
Women and patients with higher initial BMI showed higher odds of achieving clinically significant weight loss of 10% or more.
The study emphasizes the importance of managing patient expectations and highlights the need for continued research on long-term use and persistence with GLP-1 RA medications.